3-hydroxy-N'-(4-methoxybenzoyl)naphthalene-2-carbohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-hydroxy-N'-(4-methoxybenzoyl)naphthalene-2-carbohydrazide
• 化学式: C₁₉H₁₆N₂O₄
• 分子量: 336.3
• InChiKey: YZUIHHHZXFRZTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION
  申请人：Neamati Nouri

  公开号：US20090093489A1

  公开（公告）日：2009-04-09

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法、含有这些化合物的药物组合物和包装产品、使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法、监测治疗的方法、基因表达谱分析的方法以及调节细胞生长、细胞周期、细胞凋亡或基因表达的方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function
  申请人：Neamati Nouri

  公开号：US20100120781A1

  公开（公告）日：2010-05-13

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  该专利涉及新型化合物，用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及细胞生长、细胞周期、凋亡或基因表达的调节方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
  申请人：NEAMATI Nouri

  公开号：US20110034472A1

  公开（公告）日：2011-02-10

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及调节细胞生长、细胞周期、凋亡或基因表达的方法。
• ANDROGEN RECEPTOR LIGANDS
  申请人：Lloyd David George

  公开号：US20140357682A1

  公开（公告）日：2014-12-04

  Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (AR) is a member of the Nuclear Receptor (NR) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (DHT). Synthetic androgens and anti-androgens have therapeutic value in the treatment of various androgen dependent conditions, from regulation of male fertility to prostate cancer. Current treatment of prostate cancer (PCa) typically involves administration of ‘classical’ antiandrogens, competitive inhibitors of natural AR ligands, DHT and tes, for the ligand binding pocket (LBP) in the C-terminal ligand binding domain (LBD) of the AR. However, prolonged LBP-targeting can often lead to androgen resistance and alternative therapies and therapeutic strategies are urgently required. Disclosed herein are a class of non-steroidal, small molecule AR antagonists which inhibit the transcriptional activity of the AR by non LBP-mediated modulation. The novel class reported demonstrates full (‘true’) antagonism in AR with low micromolar potency, high selectivity over both the Estrogen Receptors alpha and beta (ERα and ERβ) and the Glucocorticoid Receptor (GR) and only micromolar partial antagonism in the Progesterone Receptor (PR). Data provide compelling evidence for such non-LBP intervention as an alternative approach to classical PCa therapy. (Formula I).
• US9296716B2
  申请人：——

  公开号：US9296716B2

  公开（公告）日：2016-03-29